Patents by Inventor Arthur Taveras

Arthur Taveras has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080221091
    Abstract: The present invention relates generally to pharmaceutical agents containing a heterocyclic moiety, and in particular, to heterocyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterocyclic MMP-13 inhibiting compounds with a modified benzoxazine moiety, that exhibit an increased potency and selectivity in relation to currently known MMP-13 inhibitors.
    Type: Application
    Filed: March 7, 2008
    Publication date: September 11, 2008
    Inventors: Christian Gege, Arthur Taveras
  • Publication number: 20080221092
    Abstract: The present invention relates generally to amide containing heterobicyclic containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-3 and/or MMP-13 inhibiting compounds that exhibit an increased potency and selectivity in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: September 11, 2008
    Inventors: Harald Bluhm, Matthias Hochgurtel, Heiko Kroth, Michael Essers, Christian Gege, Frank Richter, Arthur Taveras
  • Publication number: 20080207607
    Abstract: The present invention relates generally to azatriocyclic containing pharmaceutical agents, and in particular, to azatricyclic metalloprotease inhibiting compounds. More particularly, the present invention provides a new class of azatricyclic MMP-3, MMP-8 and/or MMP-13 inhibiting compounds, that exhibit an increased potency and selectivity in relation to currently known MMP-13, MMP-8 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: August 28, 2008
    Inventors: Christian Gege, Carine Chevrier, Matthias Schneider, Harald Bluhm, Matthias Hochgurtel, Hongbo Deng, Brian M. Gallagher, Irving Sucholeiki, Arthur Taveras
  • Publication number: 20080176870
    Abstract: The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
    Type: Application
    Filed: November 20, 2007
    Publication date: July 24, 2008
    Inventors: Bert Nolte, Irving Sucholeiki, Tim Feuerstein, Brian M. Gallagher, Xinyuan Wu, Christoph Steeneck, Christian Gege, Hongbo Deng, Joshua Van Veldhuizen, Arthur Taveras
  • Publication number: 20080161300
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: December 7, 2007
    Publication date: July 3, 2008
    Applicant: Alantos Pharmaceuticals Holding, Inc.
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochgurtel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Beisinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
  • Publication number: 20080090823
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: September 26, 2007
    Publication date: April 17, 2008
    Inventors: Purakkattle Biju, Arthur Taveras, J. Merritt, John Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia Aki, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani
  • Publication number: 20080021024
    Abstract: The present invention relates to amide containing aromatic MMP inhibiting compounds with a mono-amide heteroaromatic group, of formulas I and II:
    Type: Application
    Filed: June 29, 2007
    Publication date: January 24, 2008
    Inventors: Irving Sucholeiki, Christian Gege, Brian Gallagher, Timothy Powers, Hongbo Deng, Xinyuan Wu, Christoph Steeneck, Andrew Kiely, Arthur Taveras
  • Publication number: 20070264230
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, acute pain, acute and chronic inflammatory pain, and neuropathic pain using a compound of formula IA.
    Type: Application
    Filed: January 9, 2007
    Publication date: November 15, 2007
    Inventors: Arthur Taveras, Jianhua Chao, Purakkattle Biju, Younong Yu, Jay Fine, William Hipkin, Cynthia Aki, J. Merritt, Ge Li, John Baldwin, Gaifa Lai, Minglang Wu, Evan Hecker
  • Publication number: 20070248594
    Abstract: The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
    Type: Application
    Filed: July 10, 2007
    Publication date: October 25, 2007
    Inventors: Jianhua Chao, Arthur Taveras, Cynthia Aki, Daniel Lundell, Jay Fine, Tony Priestley, Angelo Reggiani
  • Publication number: 20070155737
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic ADAMTS-4 inhibiting compounds.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 5, 2007
    Inventors: Brian Gallagher, Joshua Van Veldhuizen, Xinyuan Wu, Hongbo Deng, Irving Sucholeiki, Matthias Hochguertel, Harald Bluhm, Arthur Taveras
  • Publication number: 20070155738
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting and MMP-3 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 and MMP-3 inhibitors.
    Type: Application
    Filed: November 20, 2006
    Publication date: July 5, 2007
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Heiko Kroth, Matthias Hochguertel, Michael Essers, Joshua Van Veldhuizen, Bert Nolte, Brian Gallagher, Tim Feuerstein, Matthias Schneider, Torsten Arndt, Hongbo Deng, Ralf Biesinger, Xinyuan Wu, Harald Bluhm, Irving Sucholeiki, Arthur Taveras
  • Publication number: 20070155756
    Abstract: Methods of treating chemokine-mediated diseases are disclosed. The methods comprise the administration of CXC-Chemokine receptor antagonists of the formula or pharmaceutically acceptable salts or solvates thereof, in combination with other classes of pharmaceutical compounds. The chemokine-mediated diseases include acute and chronic inflammatory disorders, psoriasis, cystic fibrosis, asthma and cancer. Also disclosed are novel compounds of formula (I).
    Type: Application
    Filed: February 14, 2007
    Publication date: July 5, 2007
    Inventors: Arthur Taveras, Motasim Billah, Daniel Lundell, William Kreutner, James Jakway, Jay Fine, Loretta Bober, Jianhua Chao, Purakkattle Biju, Younong Yu
  • Publication number: 20070021494
    Abstract: There are disclosed compounds of the formula or a pharmaceutically acceptable salt or solvate thereof which are useful for the treatment of chemokine-mediated diseases such as acute and chronic inflammatory disorders and cancer.
    Type: Application
    Filed: August 8, 2006
    Publication date: January 25, 2007
    Inventors: Arthur Taveras, Cynthia Aki, Richard Bond, Jianping Chao, Michael Dwyer, Johan Ferreira, Jianhua Chao, Younong Yu, John Baldwin, Bernd Kaiser, Ge Li, J. Merritt, Purakkattle Biju, Kingsley Nelson, Laura Rokosz, Gaifa Lai, James Jakway, Minglang Wu, Evan Hecker, Daniel Lundell, Jay Fine
  • Publication number: 20060293345
    Abstract: The present invention relates generally to amide group containing pharmaceutical agents, and in particular, to amide containing heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic MMP-13 inhibiting compounds, that exhibit an increased potency in relation to currently known MMP-13 inhibitors.
    Type: Application
    Filed: May 22, 2006
    Publication date: December 28, 2006
    Inventors: Christoph Steeneck, Christian Gege, Frank Richter, Matthias Hochguertel, Tim Feuerstein, Harald Bluhm, Irving Sucholeiki, Jurgen Boer, Xinyuan Wu, Matthias Schneider, Bert Nolte, Brian Gallagher, Joshua Van Veldhuizen, Hongbo Dong, Michael Essers, Heiko Kroth, Andrew Kiely, Timothy Powers, Arthur Taveras
  • Publication number: 20060270701
    Abstract: The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.
    Type: Application
    Filed: April 21, 2006
    Publication date: November 30, 2006
    Inventors: Heiko Kroth, Tim Feuerstein, Frank Richter, Jurgen Boer, Michael Essers, Bert Nolte, Matthias Schneider, Matthias Hochguertel, Fritz-Frieder Frickel, Arthur Taveras
  • Publication number: 20060223864
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and ischemia reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: December 16, 2004
    Publication date: October 5, 2006
    Inventors: Purakkattle Biju, Arthur Taveras, J. Merritt, John Baldwin, Younong Yu, Junying Zheng, Jianhua Chao, Cynthia Aki, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani
  • Publication number: 20060173183
    Abstract: The present invention relates generally to bis-amide group containing pharmaceutical agents, and in particular, to multicyclic bis-amide MMP-13 inhibitor compounds. More particularly, the present invention provides a new class of MMP-13 inhibiting compounds, containing a pyrimidinyl bis-amide group in combination with a heterocyclic moiety, that exhibit an increased potency and solubility in relation to currently known bis-amide group containing MMP-13 inhibitors.
    Type: Application
    Filed: December 30, 2005
    Publication date: August 3, 2006
    Inventors: Timothy Powers, Christoph Steeneck, Ralf Biesinger, Harald Bluhm, Hongbo Deng, Rory Dodd, Brian Gallagher, Christian Gege, Matthias Hochgurtel, Andrew Kiely, Frank Richter, Matthias Schneider, Irving Sucholeiki, Joshua Van Veldhuizen, Xinyuan Wu, Arthur Taveras
  • Publication number: 20060025453
    Abstract: Disclosed are novel compounds of the formula: and the pharmaceutically acceptable salts and solvates thereof. D and E are different groups wherein one is N and the other is CR50. Examples of groups comprising Substituent A include heteroaryl, aryl, heterocycloalkyl, cycloalkyl, aryl, alkynyl, alkenyl, aminoalkyl, alkyl or amino. Examples of groups comprising Substituent B include aryl and heteroaryl. Also disclosed is a method of treating a chemokine mediated diseases, such as, cancer, angiogenisis, angiogenic ocular diseases, pulmonary diseases, multiple sclerosis, rheumatoid arthritis, osteoarthritis, stroke and cardiac reperfusion injury, pain (e.g., acute pain, acute and chronic inflammatory pain, and neuropathic pain) using a compound of formula IA.
    Type: Application
    Filed: December 20, 2004
    Publication date: February 2, 2006
    Inventors: Arthur Taveras, J. Merritt, John Baldwin, Junying Zheng, Purakkattle Biju, Younong Yu, Jianhua Chao, Jay Fine, Daniel Lundell, Tony Priestley, Angelo Reggiani, Gaifa Lai, Minglang Wu
  • Publication number: 20060014794
    Abstract: The present invention is directed to a compound having the general structure of formula (1): useful for the treatment, prevention or amelioration of a CXCR1 or CXCR2 chemokine-mediated disease.
    Type: Application
    Filed: May 11, 2005
    Publication date: January 19, 2006
    Inventors: Jianhua Chao, Arthur Taveras, Cynthia Aki, Daniel Lundell, Jay Fine, Tony Priestley, Angelo Reggiani
  • Publication number: 20050192345
    Abstract: The present invention relates to four distinct crystalline polymorphs of a monohydrate of Compound A having the following chemical structure: These four polymorphic forms, herein referred to as Forms I, II, III and IV are active as a CXC-chemokine receptor ligands. The invention is further directed to formulations, methods of treatment, and processes of synthesis of these polymorphic forms.
    Type: Application
    Filed: January 28, 2005
    Publication date: September 1, 2005
    Inventors: Mengwei Hu, Younong Yu, Michael Dwyer, Arthur Taveras, Agnes Kim-Meade, Jianguo Yin, Xiaoyong Fu, Timothy McAllister, Shuyi Zhang, Kevin Klopfer